What is MSInsight?
MSInsight is dedicated to empowering the fight against cancer by revealing actionable information from the genome. The company is developing a portfolio of advanced diagnostic solutions for Microsatellite Instability (MSI) status, which serves as an indicator of treatment response and a pan-cancer biomarker. Utilizing Next-Generation Sequencing data, MSInsight aims to provide bioinformatic tools that deliver insights into microsatellite mutational variations. Their flagship product, MSIcare, is positioned as a comprehensive diagnostic, prognostic, and theranostic assistant designed to guide clinical decision-making in oncology.
How much funding has MSInsight raised?
MSInsight has raised a total of $1.7M across 1 funding round:
Angel/Seed
$1.7M
Angel/Seed (2025): $1.7M with participation from Bpifrance, Calyseed, and Capital Cell
Key Investors in MSInsight
Bpifrance
Bpifrance is a French public investment bank that finances companies at all stages of development, supporting them with credit, guarantees, and equity, as well as innovation and international expansion.
Calyseed
Calyseed is a healthcare startup fund focused on supporting early-stage medical technology companies, providing initial investments and guidance to foster growth and scientific impact.
Capital Cell
Capital Cell is Europe's pioneering equity crowdfunding platform specializing in life sciences, known for its rigorous due diligence procedures in selecting investment opportunities.
What's next for MSInsight?
The recent major strategic investment signals a new phase of growth and development for MSInsight, likely enabling the company to accelerate the commercialization of its MSIcare platform and expand its research and development capabilities. This substantial backing from prominent investors suggests confidence in MSInsight's innovative approach to cancer diagnostics and its potential to significantly impact patient treatment outcomes. The company is poised to further solidify its position in the healthtech sector, leveraging its genomic insights to guide therapeutic strategies and improve the efficacy of cancer treatments.
See full MSInsight company page
